CryoPort Stock News

Cryoport, Inc. (CYRX) is the leading provider of temperature-controlled supply chain solutions for the rapidly growing cell and gene therapy industry. CYRX supports 745 clinical trials and 19 commercial therapies, with commercial segment revenue up 36% YoY, reflecting accelerating industry adoption. Despite strong growth and a dominant market position, CYRX trades at depressed valuations, offer...

Annual Awards Program Recognizes Breakthrough Life Sciences & Biotechnology Innovation Around the World Annual Awards Program Recognizes Breakthrough Life Sciences & Biotechnology Innovation Around the World

Cryoport, Inc. ( CYRX ) Q3 2025 Earnings Call November 4, 2025 5:00 PM EST Company Participants Jerrell Shelton - Chairman, President & CEO Robert Stefanovich - Senior VP, CFO, Treasurer & Chief Administrative Officer Mark W. Sawicki - Senior VP & Chief Scientific Officer Thomas Heinzen - Vice President of Corporate Development & Investor Relations Conference Call Participants Todd Fromer - Kan...

Third quarter revenue increased 15% year-over-year to $44.2 million Commercial Cell & Gene Therapy revenue increased 36% year-over-year to $8.3 million Life Sciences Services revenue grew 16% year-over-year, including a 21% rise in BioStorage/BioServices revenue Life Sciences Products revenue grew 15% year-over-year Company updates full year 2025 revenue guidance of $170 to $174 million NASHVIL...

First Global Supply Chain Solutions Company to Achieve ISO 21973 Certification, Ensuring Highest Transport Safety, Traceability, and Integrity Standards for Cell and Gene Therapies NASHVILLE, Tenn. , Oct. 30, 2025 /PRNewswire/ -- Cryoport, Inc.  (NASDAQ: CYRX) ("Cryoport" or "the Company"), a global leader in temperature-controlled supply chain solutions for the life sciences, today announced t...

NASHVILLE, Tenn. , Oct. 21, 2025 /PRNewswire/ -- Cryoport, Inc. (Nasdaq: CYRX) ("Cryoport" or the "Company"), a global leader in temperature-controlled supply chain solutions for the life sciences, today announced that the Company will report financial results for the third quarter ended September 30, 2025 on Tuesday, November 4, 2025 after U.S. markets close.

Connected, Intelligent Condition Monitoring Assets that Safeguard Vital Life Science Materials Mark MVE's First Step in its Real-Time Integrated Systems Evolution NASHVILLE, Tenn. , Oct. 7, 2025 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX), a global leader in supply chain solutions for the life sciences, today announced the unveiling of  MVE Biological Solutions ' ("MVE") integrated Condition ...

The 55,000-Square-Foot Facility is the Latest Addition to Cryoport Systems' Global Supply Chain Center Network Designed to Support Complex Life Sciences Supply Chain Needs, Including Biologistics, BioServices and Future Cryopreservation Services Worldwide NASHVILLE, Tenn. , Oct. 1, 2025 /PRNewswire/ -- Cryoport, Inc.  (NASDAQ: CYRX) ("Cryoport" or "the Company"), a global leader in temperature-...